Novel Fluorescent Agent Helps Guide Removal of Ovarian Cancer Tumors

The researchers also measured tolerability and pharmacokinetics, and whether surgeons could use the procedure.

The new fluorescent agent OTL38, which binds to Folate Receptor-alpha (FRα), was developed by researchers from Purdue University (West Lafayette, IN, USA), and was used for the first time in human subjects by researchers at the Centre for Human Drug Research (Leiden, Netherlands). According to the researchers FRα is expressed in relatively low levels in normal human tissue, but is present in more than 90% of ovarian cancer tissue.

Author of the study, Alexander L. Vahrmeijer MD, PhD, Leiden University Medical Center (LUMC; Leiden Netherlands), said, "Surgery is the most important treatment for ovarian cancer, and surgeons mainly have to rely on their naked eyes to identify tumor tissue, which is not optimal. Near infrared (NIR) fluorescence imaging is a novel technique that may assist the surgeons to improve visualization of tumors during surgery. In our study, using a tumor-specific fluorescent agent and a dedicated imaging system, a fluorescent signal was detected in tumors in real time during a surgical procedure for ovarian cancer called cytoreduction. This allowed resection of additional tumor lesions that were not visible to the surgeons' naked eyes. The main advantage of NIR light is that it can penetrate tissue in the order of centimeters, allowing the surgeon to visualize tumors underneath the tissue surface that can be detected using a dedicated imaging system."

Related Links:
Purdue University
Centre for Human Drug Research
Leiden University Medical Center